Invention Grant
- Patent Title: Isoquinoline derivatives as MGAT2 inhibitors
-
Application No.: US15104537Application Date: 2015-01-20
-
Publication No.: US10065945B2Publication Date: 2018-09-04
- Inventor: Richard Berger , Timothy A. Blizzard , Brian T. Campbell , Helen Y. Chen , John S. Debenham , Sunita V. Dewnani , Byron Dubois , Candido Gude , Zack Zhiqiang Guo , Bart Harper , Zhiyong Hu , Songnian Lin , Ping Liu , Ming Wang , Feroze Ujjainwalla , Jiayi Xu , Libo Xu , Rui Zhang
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Janet E. Fair; Catherine D. Fitch
- International Application: PCT/US2015/011939 WO 20150120
- International Announcement: WO2015/112465 WO 20150730
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D417/14 ; C07D413/12 ; C07D471/04 ; C07D401/12
Abstract:
The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
Public/Granted literature
- US20180009796A1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS Public/Granted day:2018-01-11
Information query
